BeiGene, a Chinese biotech developing cancer therapies for China and global markets, raised $158 million by offering 6.6 million shares at $24, the high end of the range of $22 to $24. BeiGene plans to list on the Nasdaq under the symbol BGNE. Goldman Sachs, Morgan Stanley and Cowen & Company acted as lead managers on the deal.
The article Chinese cancer biotech BeiGene prices IPO at $24, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.